Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry
Physiologic Signals and Signatures With the Accuryn Monitoring System - A Retrospective and Prospective Analysis (The Accuryn Registry)
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: 1. Signed or Verbal Informed Consent as required by IRB (if applicable). 2. Adult (age ≥ 18). 3. Monitored on the Accuryn® Monitoring System during their procedure and ICU stay (for retrospective enrollment). 4. Patient is undergoing cardiac surgical intervention(s). Exclusion Criteria: 1. Known history of advanced chronic kidney disease defined by an estimated glomerular filtration rate (eGFR) \<20 mL/min/1.73m2 within 30 days prior to procedure. 2. The patient is unsuitable for the study, in the opinion of the investigator. This may include vulnerable patient populations such as pregnant women, prisoners ,or those detained in a penal institution.
Study sites (9)
CA
- Cedars-Sinai Medical Center · Los Angeles, CA 90048More trials in Los Angeles
- San Francisco VA Medical Center · San Francisco, CA 94121More trials in San Francisco
DC
- George Washington University Hospital · Washington D.C., DC 20037Gage Parr, MD · Study contact · 202-715-4000 · KPARR@mfa.gwu.eduGage Parr, MD · Principal investigatorMore trials in Washington D.C.
FL
- Cleveland Clinic Florida · Weston, FL 33331Steven Minear, MD · Study contact · 954-290-1569 · minears@ccf.orgCamila Teixeira, MD · Study contact · 954-909-1025 · decarvc@ccf.orgSteven Minear, MD · Principal investigatorMore trials in Weston
KY
- Jewish Hospital / University of Louisville · Louisville, KY 40202Terry Blanton, BSN, RN · Study contact · 502-587-4381 · mary.blanton@louisville.eduShavonne Silvers, LPN · Study contact · 5026815171 · shavonne.silvers@louisville.eduJiapeng Huang, MD, PhD · Principal investigatorMore trials in Louisville
NC
- Mission Health Hospital · Asheville, NC 28803Leslie McPeters, MSN, FNP · Study contact · 828-213-5679 · leslie.mcpeters@hcahealthcare.comLynne Hampton, MBA, RN · Study contact · 828.213.5631 · Lynne.Hampton@hcahealthcare.comMark Groh, MD · Principal investigatorMore trials in Asheville
- Duke University Hospital · Durham, NC 27710Madhav Swaminathan, MD · Study contact · 919-681-6532 · madhav.swaminathan@duke.eduMadhav Swaminathan, MD · Principal investigatorMore trials in Durham
- Wake Forest Baptist Medical Center · Winston-Salem, NC 27157More trials in Winston-Salem
OH
- Cleveland Clinic · Cleveland, OH 44195Michael Kot, MD · Study contact · 216-442-6616 · kotm@ccf.orgMichael Kot, MD · Principal investigatorMore trials in Cleveland